Abstract
A recent study, published in Nature, identifies the methylcytosine dioxygenase 2 (TET2) as an epigenetic modifier that is regulated in response to glucose availability and mechanistically links higher cancer susceptibility in patients with diabetes to high blood glucose levels.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have